Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase II clinical data demonstrate efficacy for an antibody to treat adipocytic sarcoma

Nov. 11, 2013

Prima Biomed grants CVac license to Neopharm for Israel

Nov. 7, 2013

IDMC recommends continuation of Cel-Sci's pivotal trial of Multikine

Nov. 7, 2013

ImmunoGen discontinues IMGN-901 study in small-cell lung cancer

Nov. 6, 2013

3pRNA RIG-I agonist displays activity against melanoma

Nov. 6, 2013

CureVac collaborates with the Cancer Research Institute and Ludwig Cancer Research

Nov. 6, 2013

arGEN-X and de Duve Institute/UCL sign collaboration to develop immunomodulation therapy for cancer

Nov. 5, 2013

Farletuzumab misses phase II endpoint for NSCLC

Nov. 5, 2013

SymBio and Eisai discontinue Japanese phase II trial of Treakisym

Nov. 4, 2013

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Oct. 30, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...